BPMU.F Stock Overview
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF44.45 |
| 52 Week High | CHF50.00 |
| 52 Week Low | CHF38.60 |
| Beta | 0.58 |
| 1 Month Change | 9.08% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -1.33% |
| 5 Year Change | 2.22% |
| Change since IPO | -11.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| BPMU.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 3.9% | 3.3% |
| 1Y | n/a | 3.4% | 25.8% |
Return vs Industry: Insufficient data to determine how BPMU.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BPMU.F performed against the US Market.
Price Volatility
| BPMU.F volatility | |
|---|---|
| BPMU.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BPMU.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BPMU.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 147 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.
Basilea Pharmaceutica AG Fundamentals Summary
| BPMU.F fundamental statistics | |
|---|---|
| Market cap | US$540.76m |
| Earnings (TTM) | US$11.50m |
| Revenue (TTM) | US$173.50m |
47.0x
P/E Ratio3.1x
P/S RatioIs BPMU.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPMU.F income statement (TTM) | |
|---|---|
| Revenue | CHF157.63m |
| Cost of Revenue | CHF104.65m |
| Gross Profit | CHF52.99m |
| Other Expenses | CHF42.54m |
| Earnings | CHF10.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 13, 2024
| Earnings per share (EPS) | 0.87 |
| Gross Margin | 33.61% |
| Net Profit Margin | 6.63% |
| Debt/Equity Ratio | -1,108.7% |
How did BPMU.F perform over the long term?
See historical performance and comparison